학술논문
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
Document Type
Article
Author
Diéras, Véronique; Wildiers, Hans; Jassem, Jacek; Dirix, Luc Y.; Guastalla, Jean-Paul; Bono, Petri; Hurvitz, Sara A.; Gonçalves, Anthony; Romieu, Gilles; Limentani, Steven A.; Jerusalem, Guy; Lakshmaiah, K.C.; Roché, Henri; Sánchez-Rovira, Pedro; Pienkowski, Tadeusz; Seguí Palmer, Miguel Ángel; Li, Ai; Sun, Yu-Nien; Pickett, Cheryl A.; Slamon, Dennis J.
Source
In The Breast June 2015 24(3):182-190
Subject
Language
ISSN
0960-9776